Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSME-IMMUN Rapid Immunization Schedule in Adults
NCT00460486Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Nov 2007
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label trial of FSME-IMMUN in tick-borne encephalitis (TBE) (2 arms), sponsored by Pfizer. Primary endpoint: Seropositivity rate as determined by Enzyme-Linked Immunosorbent Assay (ELISA) and Neutralization test (NT). Started Sep 2006; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00460486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00460486.